Skip to content

Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Mar 20, 2017
SAN DIEGO, March 20, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), a biopharmaceutical company focused on developing novel, small molecule drugs across multiple therapeutic areas, today announced the appointment of Dr. Preston Klassen, M.D., M.H.S. as Executive Vice President, Research and Development and Chief Medical Officer. D...
Mar 8, 2017
SAN DIEGO, March 8, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), a biopharmaceutical company focused on developing novel, small molecule drugs across multiple therapeutic areas, today announced that Amit Munshi, the Company's President and Chief Executive Officer will present a corporate update at the 27th Annual Oppenheimer Hea...
Feb 14, 2017
SAN DIEGO, Feb. 14, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the appointment of three new members to the company's Board of Directors.  Jayson Dallas, M.D., Oliver Fetzer, Ph.D., and Garry A. Neil, M.D. have joined as independent directors.  The new directors are all international business executives with sign...
Feb 9, 2017
SAN DIEGO, Feb. 9, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Dr. Scott Lee and Professor Tanja Kühbacher will present data on etrasimod (APD334) at the 12th Congress of European Crohn's and Colitis Organisation (ECCO) - Inflammatory Bowel Diseases 2017 on Friday, February 17.  The conference is taking...
Jan 4, 2017
SAN DIEGO, Jan. 4, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it has amended its BELVIQ® (lorcaserin HCl) marketing and supply agreement with Eisai Co., Ltd. and Eisai Inc. (collectively, "Eisai"). Under the revised agreement, Eisai is acquiring global commercialization rights to BELVIQ, including in t...
Dec 19, 2016
WOODCLIFF LAKE, N.J. and SAN DIEGO, Dec. 19, 2016 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Eisai Laboratórios Ltda., a subsidiary of Eisai Inc., has received regulatory approval from the Brazilian Health Surveillance Agency (ANVISA) for BELVIQ® (lorcaserin HCl) for chronic weight manag...
Dec 13, 2016
SAN DIEGO, Dec. 13, 2016 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Amit Munshi, the Company's President and Chief Executive Officer will present a corporate update at the 35th Annual J.P. Morgan Healthcare Conference on Thursday, January 12 at 9:00am PT. The conference will take place January 9-12, 2017, at the...
Dec 7, 2016
SAN DIEGO, Dec. 7, 2016 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it has completed enrollment in the ralinepag phase 2 trial.  Ralinepag is an oral, selective IP receptor agonist targeting the prostacyclin pathway for the treatment of pulmonary arterial hypertension (PAH). The study enrolled approximately 60 pa...
Nov 30, 2016
SAN DIEGO, Nov. 30, 2016 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that four abstracts will be presented at the 2016 Advances in Inflammatory Bowel Diseases: Crohn's & Colitis Foundation's Clinical and Research Conference on Friday, December 9 at 6:00pm ET.  The conference is taking place December 8-10 at the Walt D...
Nov 9, 2016
SAN DIEGO, Nov. 9, 2016 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Amit Munshi, the Company's President and Chief Executive Officer will present a corporate overview at the 28th Annual Piper Jaffray Healthcare Conference on Tuesday, November 29 at 1:30pm ET.  The conference will take place November 29-30, 2016 a...
Nov 9, 2016
SAN DIEGO, Nov. 9, 2016 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Professor Lucie Clapp will present a poster at the American Heart Association (AHA) Scientific Sessions 2016 on Monday, November 14 at 10:45am CT.  The scientific sessions are taking place November 12-16, 2016 in New Orleans, Louisiana at the Ern...
Nov 3, 2016
WOODCLIFF LAKE, N.J. and SAN DIEGO, Nov. 3, 2016 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the presentation of one oral presentation and one poster at Obesity Week(SM) regarding new data on BELVIQ® (lorcaserin HCl) CIV. Hosted by The Obesity Society and the American Society for Metabolic and Bari...
Oct 11, 2016
SAN DIEGO, Oct. 11, 2016 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Dr. Laurent Peyrin-Biroulet will present etrasimod S1P receptor profile data at the United European Gastroenterology Week (UEGW) Meeting on Tuesday, October 18 at 6:15am ET.  The meeting is taking place October 15-19 in Vienna, Austria.  The dat...
Oct 3, 2016
WOODCLIFF LAKE, N.J. and SAN DIEGO, Oct. 3, 2016 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the availability of BELVIQ XR® (lorcaserin HCl) CIV extended-release 20 mg tablets, a new once-daily dosing option that may help some patients achieve and maintain weight loss. "With more than 7...
Sep 1, 2016
SAN DIEGO, Sept. 1, 2016 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the formation of Beacon Discovery Inc. ("Beacon"), an independent, privately-held drug discovery incubator.  Beacon will focus on identifying and advancing molecules targeting G-Protein Coupled Receptors (GCPRs) from concept to clinic leverag...
Page:
...
Next Last
 
= add release to Briefcase